At 13.9% CAGR, Europe Human Vaccine Adjuvants Market is Projected to be Worth US$ 1,338.00 Million by 2030, says Business Market Insights

According to Business Market Insights' research, the Europe human vaccine adjuvants market was valued at US$ 472.33 million in 2022 and is expected to reach US$ 1,338.00 million by 2030, registering a CAGR of 13.9% from 2022 to 2030. Growing focus on immunization programs and rising trend of personalized vaccines are among the critical factors attributed to drive the Europe human vaccine adjuvants market growth.

Governments of various nations recognize the importance of vaccination as a cost-effective strategy to prevent and control chronic diseases. According to the WHO, immunization currently prevents 3.5-5 million deaths yearly from diseases such as diphtheria, tetanus, pertussis, influenza, and measles. As a result, governments in various nations are implementing immunization programs to reduce the incidence of diseases such as cancer, diabetes, cardiovascular diseases, and respiratory diseases. These programs often target specific populations, such as children, older people, and high-risk individuals, to ensure they are adequately protected against these chronic conditions. The United Nations International Children's Emergency Fund (UNICEF) also offers an immunization program that provides vaccines to protect children from life-threatening diseases globally. In collaboration with member nations, Gavi (a vaccine alliance), UNICEF, and other global immunization partners, WHO launched "The Big Catch-up" in 2023, a global vaccination drive to support efforts to catch up, restore, and improve routine immunization globally. These campaigns aim to increase vaccination coverage rates and reduce the spread of infectious diseases that can exacerbate chronic conditions. As a result, there is a growing demand for vaccines and adjuvants that can enhance the immune response and provide long-lasting protection against these diseases. Thus, all these factors boost the growth of the Europe human vaccine adjuvants market.

On the contrary, manufacturing complexities and regulatory challenges hampers the growth of Europe human vaccine adjuvants market.

Based on type, the Europe human vaccine adjuvants market is segmented particulate adjuvant, emulsion adjuvant, combination adjuvant, and others. The particulate adjuvant segment held 39.3% market share in 2022, amassing US$ 185.49 million. It is projected to garner US$ 518.11 million by 2030 to register 13.7% CAGR during 2022-2030.

In terms of application, the Europe human vaccine adjuvants market is categorized into influenza, hepatitis, human papilloma virus (HPV), and others. The influenza segment held 37.7% share of Europe human vaccine adjuvants market in 2022, amassing US$ 178.04 million. It is anticipated to garner US$ 522.11 million by 2030 to expand at 14.4% CAGR during 2022-2030.

By end user, the Europe human vaccine adjuvants market is segmented into pharmaceutical and biotechnology companies, CMOs and CROs, and others. The pharmaceutical and biotechnology companies segment held 49.0% share of Europe human vaccine adjuvants market in 2022, amassing US$ 231.57 million. It is projected to garner US$ 678.86 million by 2030 to expand at 14.4% CAGR from 2022 to 2030.

By country, the Europe human vaccine adjuvants market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Our regional analysis states that Germany captured 25.4% share of Europe human vaccine adjuvants market in 2022. It was assessed at US$ 120.03 million in 2022 and is likely to hit US$ 332.56 million by 2030, registering a CAGR of 13.6% during 2022-2030.

Key players operating in the Europe human vaccine adjuvants market are Creative Biolabs Inc, Croda International Plc, CSL Ltd, Dynavax Technologies Corp, Novartis AG, Novavax Inc, Phibro Animal Health Corp, Seppic SA, and SPI Pharma Inc, among others.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com